Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia
- PMID: 19620503
- DOI: 10.1161/CIRCULATIONAHA.108.834903
Epicardial substrate and outcome with epicardial ablation of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy/dysplasia
Erratum in
- Circulation. 2010 Jun 1;121(21):e424
Abstract
Background: Efficacy of endocardial ventricular tachycardia (VT) ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia may be limited by epicardial VT, right ventricular thickening, or both. We sought to characterize the endocardial versus epicardial substrate, measure right ventricular free wall thickness, and determine epicardial ablation efficacy in patients with right ventricular cardiomyopathy/dysplasia.
Methods and results: Thirteen consecutive patients (3 female; aged 43+/-15 years; range, 17 to 70 years) undergoing endocardial and epicardial sinus rhythm voltage mapping and epicardial VT ablation after failed endocardial VT ablation were included. In each patient, the low bipolar voltage area (<1.0 mV for epicardium and <1.5 mV for endocardium) was more extensive on the epicardium (95+/-47 versus 38+/-32 cm(2); P<0.001) and was uniformly marked by multicomponent and late electrograms. The basal right ventricular thickness assessed by electroanatomic map was >10 mm in 6 of 13 patients compared with 5 to 10 mm in 4 reference patients without structural disease. Twenty-seven VTs were targeted on the epicardium with the use of activation, entrainment, or pace mapping with focal/linear ablation and targeting of late potentials. Epicardial VTs were targeted opposite normal endocardium in 10 patients (77%) and/or opposite ineffective endocardial ablation sites in 11 patients (85%). During 18+/-13 months, 10 of the 13 patients (77%) had no VT, with 2 patients having only a single VT at 2 and 38 months, respectively.
Conclusions: Patients with right ventricular cardiomyopathy/dysplasia and VT after endocardial ablation have a more extensive epicardial area of electrogram abnormalities and frequently have basal right ventricular wall thickening. Epicardial substrate and VT mapping identifies targets, and ablation results in VT control.
Similar articles
-
Ablation of ventricular arrhythmias in arrhythmogenic right ventricular dysplasia/cardiomyopathy: arrhythmia-free survival after endo-epicardial substrate based mapping and ablation.Circ Arrhythm Electrophysiol. 2011 Aug;4(4):478-85. doi: 10.1161/CIRCEP.111.963066. Epub 2011 Jun 10. Circ Arrhythm Electrophysiol. 2011. PMID: 21665983
-
Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy.Circulation. 2004 Oct 19;110(16):2293-8. doi: 10.1161/01.CIR.0000145154.02436.90. Epub 2004 Oct 11. Circulation. 2004. PMID: 15477406
-
Catheter ablation of subepicardial ventricular tachycardia using electroanatomic mapping.Herz. 2003 Nov;28(7):591-7. doi: 10.1007/s00059-003-2494-8. Herz. 2003. PMID: 14689119
-
Electroanatomic mapping of the endocardium. Implication for catheter ablation of ventricular tachycardia.Herz. 2003 Nov;28(7):583-90. doi: 10.1007/s00059-003-2492-x. Herz. 2003. PMID: 14689118 Review.
-
Endo-epicardial ablation vs endocardial ablation for the management of ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: A systematic review and meta-analysis.J Cardiovasc Electrophysiol. 2020 Aug;31(8):2022-2031. doi: 10.1111/jce.14593. Epub 2020 Jun 18. J Cardiovasc Electrophysiol. 2020. PMID: 32478430
Cited by
-
Varied Presentation of Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy (ARVD/C): A Case Series.Cureus. 2023 Jan 17;15(1):e33883. doi: 10.7759/cureus.33883. eCollection 2023 Jan. Cureus. 2023. PMID: 36819412 Free PMC article.
-
Analysis of local ventricular repolarization using unipolar recordings in patients with arrhythmogenic right ventricular cardiomyopathy.J Interv Card Electrophysiol. 2020 Mar;57(2):261-270. doi: 10.1007/s10840-019-00594-z. Epub 2019 Aug 23. J Interv Card Electrophysiol. 2020. PMID: 31440875
-
Reduced desmoplakin immunofluorescence signal in arrhythmogenic cardiomyopathy with epicardial right ventricular outflow tract tachycardia.HeartRhythm Case Rep. 2018 Jul 9;5(2):57-62. doi: 10.1016/j.hrcr.2018.06.013. eCollection 2019 Feb. HeartRhythm Case Rep. 2018. PMID: 30820396 Free PMC article. No abstract available.
-
Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease.World J Cardiol. 2014 Apr 26;6(4):154-74. doi: 10.4330/wjc.v6.i4.154. World J Cardiol. 2014. PMID: 24772256 Free PMC article. Review.
-
Cardiomyopathy: pathogenesis and therapeutic interventions.MedComm (2020). 2024 Oct 25;5(11):e772. doi: 10.1002/mco2.772. eCollection 2024 Nov. MedComm (2020). 2024. PMID: 39465141 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources